ReproCELL Inc. was established in 2003 with the goal of contributing to people's health and welfare through the development of stem cell technologies. Many of ReproCELL's technologies were developed b...
ReproCELL Inc. was established in 2003 with the goal of contributing to people's health and welfare through the development of stem cell technologies. Many of ReproCELL's technologies were developed by stem cell pioneers, Prof. Norio Nakatsuji from the Institute for Frontier Medical Sciences, Kyoto University, and Prof. Hiromitsu Nakauchi from The Institute of Medical Sciences, The University of Tokyo. ReproCELL develops diverse products, with an underlying theme that focuses on stem cell technology, to address the needs of researchers and clinicians. This product range encompasses ES/iPS cells and somatic stem cells. ReproCELL's technologies, research reagents and services have applications in clinical diagnostics, drug screening and toxicity testing. ReproCELL went public in June, 2013. Stemgent, BioServe, Reinnervate became parts of ReproCELL in 2014.